Syntactx, Now Part of NAMSA

Syntactx, Now Part of NAMSA, is a leading full-service CRO specializing in complex interventional medical device and drug trials. The company is renowned for its deep expertise and is led by key thought leaders with extensive experience in clinical practice and academia. Syntactx offers solutions for market leaders, emerging companies, early-stage startups, physicians, and institutions. Its team of experts provides guidance in strategy and consulting, clinical operations, regulatory affairs, data sciences, safety, imaging core laboratory, and medical writing. Since its foundation in 2010, Syntactx has enrolled over 200,000 subjects in North America, Europe, and Asia. The company is committed to utilizing technology to assist clients in improving the lives of patients worldwide. With its team of clinical and regulatory professionals, who have firsthand experience with enrollment obstacles and regulatory challenges, Syntactx has been a trusted partner for clients seeking market approvals and broad market adoption for their innovative products.